Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Ramucirumab + Erlotinib for Lung Cancer
Recruiting1 awardPhase 3
Los Angeles, California
This trial is testing a new drug combination to treat patients with advanced lung cancer who have specific genetic changes. The treatment aims to stop cancer growth by cutting off its blood supply and blocking growth signals. One of the drugs being tested has shown significant survival benefits when combined with other treatments in advanced lung cancer.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service